Related Experiment Video
Updated: Apr 17, 2026

Author Spotlight: A Focus on Standardized Salivary Gland Ultrasound Protocol in Connective Tissue Disease Research
Published on: October 13, 2023
Use of B lymphocyte stimulator inhibitor belimumab may be associated with a decrease in the serum concentration of
Sabeeda Kadavath1, Slavica Bobic, Petros Efthimiou
1Internal Medicine, Lincoln Medical And Mental Health Center, New York, NY, USA.
Abstract:
B cell activating factor (BAFF), also called the B lymphocyte stimulator, has been known to show increased expression in primary Sjögren's syndrome (pSS) which could explain increased B cell activation characteristic of this disease. Belimumab, a fully human IgG1λ recombinant monoclonal antibody directed against B lymphocyte stimulator (Blys), has been reported to be efficacious in systemic lupus erythematosus (SLE) through its B cell-mediated action. Randomized controlled trials of belimumab in a selected target population of pSS patients are further warranted.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Clinical Applications of Epidermal Stem Cells
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
